In November 2019, the Board of Danish Regions adopted seven changes to the work of the Danish Medicines Council. Among other things, from October 2020, the Danish Medicines Council will begin using QALY to determine whether hospitals should take new medicines into use as a possible standard treatment.
Consequently, from 1 January 2020, the Danish Medicines Council Secretariat took over the task to assess health economic analyses in connection with recommendations by the Danish Medicines Council of new medicines and indicators. Employees at Amgros who previously worked with these tasks have been transferred to the Danish Medicines Council Secretariat.
This means that, in future, questions regarding the healtch economic part of applications for new medicines and indicators should be referred to the Danish Medicines Council Secretariat.
When the Danish Medicines Council has assessed the added clinical value, Amgros still negotiates the price of the medicine. The purpose of the negotiations is to agree on a price level that gives a reasonable match between the added clinical value of the medicine and its additional costs in relation to standard treatment. After this, the Danish Medicines Council decides whether it will recommend the medicine as a possible standard treatment at public hospitals. Read more about price negotiations here.
Amgros looks forward to continuing our good cooperation with our suppliers and with the Danish Medicines Council Secretariat.
Senior communication specialist
I’m responsible for overall communication at Amgros, including PR. And I help to ensure that we communicate with the surrounding world in an open and engaging manner.